Walter Reinisch, Wayne Hellstrom, Radboud J E M Dolhain, Suresh Sikka, René Westhovens, Rajiv Mehta, Timothy Ritter, Ursula Seidler, Oleksandr Golovchenko, Vladimir Simanenkov, Olena Garmish, Sławomir Jeka, Radka Moravcová, Vijay Rajendran, Franck-Olivier Le Brun, Sarah Arterburn, Timothy R Watkins, Robin Besuyen, Dirk Vanderschueren
OBJECTIVES: The phase 2 MANTA and MANTA-RAy studies aimed to determine if the oral Janus kinase 1 preferential inhibitor filgotinib affects semen parameters and sex hormones in men with inflammatory diseases. METHODS: MANTA (NCT03201445) and MANTA-RAy (NCT03926195) included men (21-65 years) with active inflammatory bowel disease (IBD) and rheumatic diseases (rheumatoid arthritis, spondyloarthritis or psoriatic arthritis), respectively. Eligible participants had semen parameters in the normal range per the WHO definition...
August 2023: Annals of the Rheumatic Diseases